| 【英語タイトル】Human Microbiome Market Report 2023-2033 : Forecasts by Product (Prebiotics, Medical Drugs, Diagnostic Tests, Skin Products), by Type (Fecal Microbiota Transplant, Live Biotherapeutics Products (LBP), Prebiotics, Post-Biotics, Precision Antibiotics), by Technology (Proteomics, Metabolomics, Genomics (16srRNA Sequencing, Shotgun Sequencing and Long Read Metagenomics)), by Application (Gastrointestinal, Infectious Diseases, Metabolic Diseases, Cancers, Gut-Brain Axis, Others ) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
|
 | ・商品コード：VGA23FB016
・発行会社（調査会社）：visiongain
・発行日：2023年1月30日
・ページ数：281
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医薬品
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Visiongain社の本調査レポートでは、世界のヒトマイクロバイオーム市場規模が2033年までに年平均25%で成長すると予測しています。本レポートは、ヒトマイクロバイオームの世界市場を徹底調査し、レポート概要、エグゼクティブサマリー、市場動向、治療別（胃腸障害、代謝障害、癌、腸脳軸、その他）分析、種類別（FMT、LBP、プレバイオティクス、ポストバイオティクス、精密抗生物質）分析、製品別（プレバイオティクス＆プロバイオティクス、医薬品、診断検査、皮膚マイクロバイオーム）分析、技術別（ゲノミクス、プロテオミクス、メタボロミクス）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報などの内容を作成しました。本書には、4D Pharma Plc.、Axial Therapeutics、BiomX、Enterobiome、Enterome、Finch Therapeutics Group Inc.、MaaT Pharma、Rebiotix Inc.,( a Ferring Pharmacetical Company)、Second Genome、Seres Therapeutics、Synlogicなどの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・市場動向
・世界のヒトマイクロバイオーム市場規模：治療別
- 胃腸障害治療における市場規模
- 代謝障害治療における市場規模
- 癌治療における市場規模
- 腸脳軸治療における市場規模
- その他治療における市場規模
・世界のヒトマイクロバイオーム市場規模：種類別
- FMTの市場規模
- LBPの市場規模
- プレバイオティクスの市場規模
- ポストバイオティクスの市場規模
- 精密抗生物質の市場規模
・世界のヒトマイクロバイオーム市場規模：製品別
- プレバイオティクス＆プロバイオティクスの市場規模
- 医薬品の市場規模
- 診断検査の市場規模
- 皮膚マイクロバイオームの市場規模
・世界のヒトマイクロバイオーム市場規模：技術別
- ゲノミクスの市場規模
- プロテオミクスの市場規模
- メタボロミクスの市場規模
・世界のヒトマイクロバイオーム市場規模：地域別
- 北米のヒトマイクロバイオーム市場規模
- ヨーロッパのヒトマイクロバイオーム市場規模
- アジア太平洋のヒトマイクロバイオーム市場規模
- 中南米のヒトマイクロバイオーム市場規模
- 中東・アフリカのヒトマイクロバイオーム市場規模
・企業情報 |
The Human Microbiome Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Big Pharma Players Striving To Gain Market Entry Through Collaboration with Microbiome Players
There has been a growing interest from the big pharma players in microbiome research. Many of the big pharma players have been supporting the start-up microbiome players for their clinical drug candidate through funding and collaborations. For instance, in July 2022, Enterome a clinical stage microbiome company signed a strategic R&D collaboration with Nestle Health Science. This license agreement primarily targeted food allergy and Inflammatory Bowel Disease (IBD) under this agreement Enterome will receive an upfront payment of €40 million (US$46.9 million) in cash and equity. In return, Nestle Health Science will be eligible to receive the royalties and sales milestone payments on commercialization of the drug candidates. In February 2021, 4D Pharma Inc. has collaborated with Merck Co Ltd. and Pfizer for its oncology and vaccines to evaluate its MRx5018 in combination with BAVENCIO for treatment of locally advanced or metastatic urothelial carcinoma. Both Merck KGaA and Pfizer Inc. will co-develop and also commercialize it in collaboration. Similarly, in January 2021, Vedanta Biosciences has received US$25 million investment fund from Pfizer as a part of breakthrough growth initiative. Vedanta will use these funds for Phase II study of VE202 indicated for treatment of Inflammatory Bowel Disease. In July 2021, Seres announced its collaboration with Nestle Health Science to co-commercialize SER-109 therapeutic drug for treatment of Clostridioides difficile infection (CDI) in U.S. and Canada. In 2019, Seres had collaborated with AstraZeneca and received US$20 million as a financial support to conduct its research activity for immuno-oncology therapies. With more pharma players are entering this market, the overall market for human microbiome is expected to foresee a staggering growth during the forecast period.
Regulatory Approvals to Challenge Market Growth
The human microbiome has a huge potential in curing and treating diseases that have been difficult to treat through conventional methods. Moreover, the use of Live Biotherapeutic Products (LBPs) has been studied to be of great potential, however lack of defined regulatory approvals for human microbiomes is hampering the growth of this market. There has not been any clearly defined segregation for LBPs and their use, especially when classifying prebiotics, probiotics, and pharmaceutical products. The U.S. FDA in 2010, first time presented draft guidance for microorganisms intended to prevent and treat diseases which got updated in 2016 to officially make a category for LBPs. Similarly, the European Pharmacopeia Commission issued a draft in 2019 with a mention of LBPs to comply with the legislation of biological medicinal products with additional specific guidelines for LBPs. There has been a clear demand from the regulatory authorities regarding the benefits against the risks of LBPs. Conventional GMP practices emphasize the removal of microbes in the final product however, human microbiome products need to be in the final product. Hence, drafting new guidelines for regulatory approvals needs detailed documentation and justification as these products differ from non-therapeutic products. Risk assessment through genomic profiling is crucial as the LBPs have the potential to transfer genes to other microbes or may metabolize other drugs or hormones in the body. To avoid this, in vitro and ex-vivo studies, and animal models studies are essential. Detailed documentation of the origin of the strain, isolation procedure, and cell banking is required. In addition, the difficulty in having consistent batches of LBPs is also a major GMP regulatory hurdle. We believe, that as the market expands there will be well-defined regulatory guidelines for conducting human microbiome studies, at present the approval process poses a major challenge for the market players of this segment.
What Questions Should You Ask before Buying a Market Research Report?
• How is the human microbiome market evolving?
• What is driving and restraining the human microbiome market?
• How will each human microbiome submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each human microbiome submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading human microbiome market broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the human microbiome drug pipeline status for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of human microbiome market projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the human microbiome market?
• Where is the human microbiome market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the human microbiome market today, and over the next 10 years:
• Our 281-page report provides 121 tables and 168 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the human microbiome market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
By Therapeutics
• Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Disorders
• Cancers
• Gut-Brain Axis
• Others
By Type
• Fecal Microbiota Transplant (FMT)
• Live Biotherapeutic Product (LBP)
• Prebiotics
• Post-Biotics
• Precision Antibiotics
By Product
• Prebiotics & Probiotics
• Medicinal Drugs
• Diagnostic Tests
• Skin Microbiome
By Technology
• Genomics
– 16SrRNA Amplicon Sequencing
– Shotgun Metagenomic Sequencing
– Longread Metagenomic Sequencing
• Proteomics
• Metabolomics
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Rest of Asia
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• Saudi Arabia
• South Africa
• UAE
• Rest of Middle East & Africa
The report also includes profiles and for some of the leading companies in the Human Microbiome Market, 2023 to 2033, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• 4D Pharma Plc.
• Axial Therapeutics
• BiomX
• Enterobiome
• Enterome
• Finch Therapeutics Group Inc.
• MaaT Pharma
• Rebiotix Inc.,( a Ferring Pharmaceutical Company)
• Second Genome
• Seres Therapeutics
• Synlogic
• Theriva Biologics (ex-Synthetic Biologics)
• Vedanta Biosciences Inc.
Overall world revenue for Human Microbiome Market, 2023 to 2033 in terms of value the market will surpass US$224 million in 2023, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Human Microbiome Market, 2023 to 2033 report help you?
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2033 for Human Microbiome Market, 2023 to 2033 Market, with forecasts by therapeutics, type, product, technology and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 21 key national markets – See forecasts for the Human Microbiome, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Taiwan among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the Human Microbiome Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Human Microbiome Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Human Microbiome Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definition
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Associated Visiongain Reports
1.9 About Visiongain
1.10 Frequently Asked Questions (FAQs)
2. Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Wide Array of Therapeutic Applications to Boost Industry Growth
3.2.1.2 Rise in Funding from Private Ventures and Government Institutes to Trigger Industry Growth
3.2.1.3 Big Pharma Players Striving to Gain Market Entry Through Collaboration with Microbiome Players
3.2.1.4 High Throughput Sequencing, Machine Learning (AI & Deep Learning) to Reinforce the Market Growth
3.2.1.5 Microbiome Biomarker Discovery Supporting the Growth of Companion Diagnostics
3.2.2 Market Restraining Factors
3.2.2.1 Regulatory Approvals to Challenge Market Growth
3.2.2.2 Formulation and Translational Manufacturing Obstacles Restraining the Market Growth
3.2.2.3 Lack of Clarity on Pricing and Reimbursement Likely to Hamper Market Growth
3.2.3 Market Opportunities
3.2.3.1 Contract Research Manufacturing Services
3.2.3.2 Nanotechnology to Support Microbiome Diagnostics
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers (Low to Medium)
3.4.2 Bargaining Power of Buyers (Medium to High)
3.4.3 Competitive Rivalry (Medium to High)
3.4.4 Threat from Substitutes (Low to Medium)
3.4.5 Threat of New Entrants (Medium to High)
3.5 PEST Analysis
4 Human Microbiome Market Analysis by Therapeutics
4.1 Key Findings
4.2 Human Microbiome Therapeutics Segment: Market Attractiveness Index
4.3 Human Microbiome Market Size Estimation and Forecast by Therapeutics
4.4 Gastro-Intestinal Disorders
4.4.1 Market Size by Region, 2023-2033 (US$ mn)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Infectious Diseases
4.5.1 Market Size by Region, 2023-2033 (US$ mn)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Metabolic Disorder
4.6.1 Market Size by Region, 2023-2033 (US$ mn)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Cancer
4.7.1 Market Size by Region, 2023-2033 (US$ mn)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Gut-Brain-Axis
4.8.1 Market Size by Region, 2023-2033 (US$ mn)
4.8.2 Market Share by Region, 2023 & 2033 (%)
4.9 Others
4.9.1 Market Size by Region, 2023-2033 (US$ mn)
4.9.2 Market Share by Region, 2023 & 2033 (%)
5 Human Microbiome Market Analysis by Type
5.1 Key Findings
5.2 Human Microbiome by Type Segment: Market Attractiveness Index
5.3 Human Microbiome Market Size Estimation and Forecast by Therapeutics
5.4 Fecal Microbiota Transplant (FMT)
5.4.1 Market Size by Region, 2023-2033 (US$ mn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Live Biotherapeutics Product (LBP)
5.5.1 Market Size by Region, 2023-2033 (US$ mn)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Prebiotics
5.6.1 Market Size by Region, 2023-2033 (US$ mn)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Post biotics
5.7.1 Market Size by Region, 2023-2033 (US$ mn)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Precision Antibiotics
5.8.1 Market Size by Region, 2023-2033 (US$ mn)
5.8.2 Market Share by Region, 2023 & 2033 (%)
6 Human Microbiome Market Analysis by Product
6.1 Key Findings
6.2 Human Microbiome by Product Segment: Market Attractiveness Index
6.3 Human Microbiome Market Size Estimation and Forecast by Product
6.4 Prebiotics & Probiotics
6.4.1 Market Size by Region, 2023-2033 (US$ mn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Medicinal Drugs
6.5.1 Market Size by Region, 2023-2033 (US$ mn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Diagnostic Tests
6.6.1 Market Size by Region, 2023-2033 (US$ mn)
6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Skin Microbiome
6.7.1 Market Size by Region, 2023-2033 (US$ mn)
6.7.2 Market Share by Region, 2023 & 2033 (%)
7 Human Microbiome Market Analysis by Technology
7.1 Key Findings
7.2 Human Microbiome by Technology Segment: Market Attractiveness Index
7.3 Human Microbiome Market Size Estimation and Forecast by Technology
7.4 Genomics
7.4.1 Market Size by Region, 2023-2033 (US$ mn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.4.3 Genomics Market by Sequencing Type
7.4.4 16SrRNA Amplicon Sequencing
7.4.5 Shotgun Metagenomic Sequencing
7.4.6 Longread Metagenomic Sequencing
7.5 Proteomics
7.5.1 Market Size by Region, 2023-2033 (US$ mn)
7.5.2 Market Share by Region, 2023 & 2033 (%)
7.6 Metabolomics
7.6.1 Market Size by Region, 2023-2033 (US$ mn)
7.6.2 Market Share by Region, 2023 & 2033 (%)
8 Human Microbiome Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Human Microbiome Market Analysis
9.1 Key Findings
9.2 North America Human Microbiome Market Attractiveness Index
9.3 North America Human Microbiome Market by Country, 2023, 2028 & 2033 (US$ mn)
9.4 North America Human Microbiome Market Size Estimation and Forecast by Country
9.5 North America Human Microbiome Market Size Estimation and Forecast by Therapeutics
9.6 North America Human Microbiome Market Size Estimation and Forecast by Technology
9.7 North America Human Microbiome Market Size Estimation and Forecast by Type
9.8 North America Human Microbiome Market Size Estimation and Forecast by Product
9.9 U.S. Human Microbiome Market Analysis
9.10 Canada Human Microbiome Market Analysis
10 Europe Human Microbiome Market Analysis
10.1 Key Findings
10.2 Europe Human Microbiome Market Attractiveness Index
10.3 Europe Human Microbiome Market by Country, 2023, 2028 & 2033 (US$ mn)
10.4 Europe Human Microbiome Market Size Estimation and Forecast by Country
10.5 Europe Human Microbiome Market Size Estimation and Forecast by Therapeutics
10.6 Europe Human Microbiome Market Size Estimation and Forecast by Technology
10.7 Europe Human Microbiome Market Size Estimation and Forecast by Type
10.8 Europe Human Microbiome Market Size Estimation and Forecast by Product
10.9 Germany Human Microbiome Market Analysis
10.10 UK Human Microbiome Market Analysis
10.11 France Human Microbiome Market Analysis
10.12 Italy Human Microbiome Market Analysis
10.13 Spain Human Microbiome Market Analysis
10.14 Rest of Europe Human Microbiome Market Analysis
11 Asia-Pacific Human Microbiome Market Analysis
11.1 Key Findings
11.2 Asia-Pacific Human Microbiome Market Attractiveness Index
11.3 Asia-Pacific Human Microbiome Market by Country, 2023, 2028 & 2033 (US$ mn)
11.4 Asia-Pacific Human Microbiome Market Size Estimation and Forecast by Country
11.5 Asia-Pacific Human Microbiome Market Size Estimation and Forecast by Therapeutics
11.6 Asia-Pacific Human Microbiome Market Size Estimation and Forecast by Technology
11.7 Asia-Pacific Human Microbiome Market Size Estimation and Forecast by Type
11.8 Asia-Pacific Human Microbiome Market Size Estimation and Forecast by Product
11.9 China Human Microbiome Market Analysis
11.10 Japan Human Microbiome Market Analysis
11.11 South Korea Human Microbiome Market Analysis
11.12 Taiwan Human Microbiome Market Analysis
11.13 India Human Microbiome Market Analysis
11.14 Rest of Asia Pacific Human Microbiome Market Analysis
12 Latin America Human Microbiome Market Analysis
12.1 Key Findings
12.2 Latin America Human Microbiome Market Attractiveness Index
12.3 Latin America Human Microbiome Market by Country, 2023, 2028 & 2033 (US$ mn)
12.4 Latin America Human Microbiome Market Size Estimation and Forecast by Country
12.5 Latin America Human Microbiome Market Size Estimation and Forecast by Therapeutics
12.6 Latin America Human Microbiome Market Size Estimation and Forecast by Technology
12.7 Latin America Human Microbiome Market Size Estimation and Forecast by Type
12.8 Latin America Human Microbiome Market Size Estimation and Forecast by Product
12.9 Brazil Human Microbiome Market Analysis
12.10 Mexico Human Microbiome Market Analysis
12.11 Rest of Latin America Human Microbiome Market Analysis
13 Middle East & Africa Human Microbiome Market Analysis
13.1 Key Findings
13.2 Middle East & Africa Human Microbiome Market Attractiveness Index
13.3 Middle East & Africa Human Microbiome Market by Country, 2023, 2028 & 2033 (US$ mn)
13.4 Middle East & Africa Human Microbiome Market Size Estimation and Forecast by Country
13.5 Middle East & Africa Human Microbiome Market Size Estimation and Forecast by Therapeutics
13.6 Middle East & Africa Human Microbiome Market Size Estimation and Forecast by Technology
13.7 Middle East & Africa Human Microbiome Market Size Estimation and Forecast by Type
13.8 Middle East & Africa Human Microbiome Market Size Estimation and Forecast by Product
13.9 Saudi Arabia Human Microbiome Market Analysis
13.10 UAE Human Microbiome Market Analysis
13.11 South Africa Human Microbiome Market Analysis
13.12 Rest of Middle East & Africa Human Microbiome Market Analysis
14 Company Profiles
14.1 Company Share Analysis
14.2 Key Business Strategy Analysis
14.3 Rebiotix Inc., (now a Ferring Company)
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2019-2021
14.3.3.2 R&D, 2019-2021
14.3.4 Rebiotix, Inc.: Pipeline Status
14.3.5 Strategic Outlook
14.4 Seres Therapeutics, Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Revenue, 2017-2021
14.4.3.2 R&D, 2017-2021
14.4.4 Seres Therapeutics, Inc., Pipeline Status
14.4.5 Strategic Outlook
14.5 4D Pharma plc
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Revenue, 2017-2021
14.5.3.2 R&D, 2017-2021
14.5.4 4D Pharma plc: Pipeline Status
14.5.5 Strategic Outlook
14.6 Enterobiome
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Enterobiome: Pipeline Status
14.6.4 Strategic Outlook
14.7 Vedanta Biosciences, Inc.,
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Revenue, 2017-2021
14.7.4 Vedanta Biosciences, Inc.: Pipeline Status
14.7.5 Strategic Outlook
14.8 Second Genome
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Second Genome Inc.: Pipeline Status
14.8.4 Strategic Outlook
14.9 Finch Therapeutics Group Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Revenue, 2020-2021
14.9.3.2 R&D, 2020-2021
14.9.4 Finch Therapeutics Group, Inc.: Pipeline Status
14.9.5 Strategic Outlook
14.10 Enterome
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Enterome: Pipeline Status
14.10.4 Strategic Outlook
14.11 Theriva Biologics (ex-Synthetic Biologics)
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Revenue, 2017-2021
14.11.3.2 R&D, 2017-2021
14.11.4 Theriva Biologics: Pipeline Status
14.11.5 Strategic Outlook
14.12 Synlogic
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.4 Partnerships/ Strategic Collaborations
14.12.5 Strategic Outlook
14.13 Axial Therapeutics
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.4 Axial Therapeutics: Pipeline Status
14.13.5 Strategic Outlook
14.14 MaaT Pharma
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.4 MaaT Pharma: Pipeline Status
14.14.5 Strategic Outlook
14.15 BiomX
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 BiomX: Pipeline Status
14.15.4 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
